Lumida
/ANRO
⌘K
Alto Neuroscience Inc

Alto Neuroscience Inc

ANRO
$32.00USD↑+1.01%+0.32 today

MARKET CAP

1.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$31 – $33

52W RANGE

$4
$37

AI Summary

Stalk
Sell NowMedium

ANRO has decisively broken below short-term EMAs and a prior support cluster on strong volume, confirming continued medium-term bearish control. Short-term momentum is down with price trading below the 9- and 20-day EMAs and RSI trending lower, favoring selling into any rebounds near the broken EMA and support zone. The longer-term uptrend remains intact with price above the 200-day SMA, limiting bearish conviction and signaling that rallies may provide optimal entry points for further selling.

  • ↑Stock gained 9.2% over past two weeks, signaling strong momentum factors.
  • ↑“Moderate Buy” consensus with $36.63 target implies 25.8% upside.
  • ↓EPS expected to fall from ($3.14) to ($3.56), indicating financial strain.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Alto Neuroscience, Inc. (ANRO) is an emerging biotechnology company specializing in neuroscience-based therapeutics for mental health disorders. They are focused on developing innovative treatments in a specialized segment of the healthcare industry, capitalizing on the rising demand for effective solutions for conditions such as depression and anxiety. ANRO is positioned within the growth of mental health therapeutics, making it a part of the broader trend in increasing recognition and treatment of mental health issues.

Bull says

  • ↑Stock gained 9.2% over past two weeks, signaling strong momentum factors.
  • ↑“Moderate Buy” consensus with $36.63 target implies 25.8% upside.
  • ↑52-week highs and robust hedge-fund backing enhance liquidity and interest.
  • ↑Positive technical stability suggests underlying price support amid volatility.
  • ↑Niche neuroscience focus taps growing mental health therapeutics market.
  • ↑Momentum and institutional ownership factors support further upside potential.

Bear says

  • ↓EPS expected to fall from ($3.14) to ($3.56), indicating financial strain.
  • ↓Negative profitability factors and P/E of –12.0 highlight cash burn issues.
  • ↓Elevated leverage risk and weak liquidity may constrain growth.
  • ↓Short interest up 4.5% reflects waning investor confidence.
  • ↓Size and liquidity issues could amplify volatility in downturns.
  • ↓Downward earnings revisions and weak profitability factors pose headwinds.